Asymmetrical dimethylarginine level in atrial fibrillation

Cengel A., ŞAHİNARSLAN A., BİBEROĞLU G., Hasanoglu A., Tavil Y., Tulmac M., ...Daha Fazla

ACTA CARDIOLOGICA, cilt.63, sa.1, ss.33-37, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.2143/ac.63.1.2025329
  • Dergi Adı: ACTA CARDIOLOGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.33-37
  • Anahtar Kelimeler: ADMA, thrombosis, endothelial dysfunction, COAGULATION, INHIBITOR
  • Gazi Üniversitesi Adresli: Evet

Özet

Objective - Atrial fibrillation (AF) is known to be related with increased risk of thromboembolic events. Asymmetrical dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS), can cause endothelial dysfunction by decreasing nitric oxide (NO) and lead to increased risk of thrombosis. In the present study our aim was to compare plasma levels of ADMA in patients with acute onset (< 24 hours) and chronic AF (> I year) to determine the risk of thrombosis.